A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

Heitzmann, Edwige; Javelot, Hervé; Weiner, Luisa; Michel, Bruno

doi:10.1155/2016/7031245

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effects cited in cases of discontinuation were fatigue, insomnia, restlessness, anxiety, and deficits in attention. Of note, long-term use of antipsychotics like aripiprazole may be associated with more severe adverse effects such as tardive dyskinesia, with risk factors including older age and female sex [ 161 , 162 ].…”

Section: Pharmacological Treatments For Audmentioning

confidence: 99%

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Burnette

Nieto

Grodin

et al. 2022

Drugs

View full text Add to dashboard Cite

Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.

show abstract

Section: Pharmacological Treatments For Audmentioning

confidence: 99%

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Burnette

Nieto

Grodin

et al. 2022

Drugs

View full text Add to dashboard Cite

show abstract

“…[30][31][32][33]), (2) adverse effects (e.g. [34][35][36][37][38][39]); in these two first sections, we described two cases in which clinical decisions were assisted by TDM [32,36]. "Pharmacopsy Alsace" is also involved in studies focusing on appropriate psychotropic use [40,41], the development of prescription support tools (anticholinergic impregnation scale for French psychiatry [42]) and training/information on psychotropic drugs [41,43].…”

Section: Contribution Of a New Partnership Approach Between Psychopha...mentioning

confidence: 99%

Enhancing the role played by clinical pharmacists in psychiatric settings to better integrate clinical psychopharmacology into the decision-making process

Javelot

Dizet²,

Straczek

et al. 2021

Therapies

View full text Add to dashboard Cite

“…Another case, published by Edwige et al (2016) , describes a 74-year-old man who was treated for an episode of depression with escitalopram (10 mg/day) and aripiprazole (5 mg/day), although no delirium or melancholic symptoms were observed, which means that the combination seemed inappropriate. After 9 months of treatment, aripiprazole was suspended for dyskinesia of mouth, tongue and face and chorea in the limbs.…”

Section: Case Presentationmentioning

confidence: 99%

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin

Aguilar¹,

Lorenzo

Fernández-Ovejero

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

We report on a patient with tardive dyskinesia (TDK) treated with aripiprazole, a third-generation antipsychotic with partial D2 agonist-antagonist activity at both the dopamine and serotonin receptors. The patient’s condition improved with administration of a combination of tetrabenazine, botulinum toxin, and clozapine, which has previously not been used. We suggest that this treatment combination may have potential benefits for patients with TDK. After aripiprazole discontinuation, the patient was treated with clozapine (150 mg/day) and biperiden (8 mg/day). Due to a lack of improvement, we administered 300 units (intramuscularly; IM) of botulinum toxin into the paravertebral muscles every 3 months and 1,000 units IM every 4 months in addition to tetrabenazine (75 mg/day) and biperiden (8 mg/day). The patient stopped this treatment, at which point TDK reappeared. After starting a treatment regimen of clozapine (100 mg/day), tetrabenazine (75 mg/day), and botulinum toxin (300 units IM), the patient’s symptoms remitted.

show abstract

A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

Cited by 4 publications

References 14 publications

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Enhancing the role played by clinical pharmacists in psychiatric settings to better integrate clinical psychopharmacology into the decision-making process

Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin

Contact Info

Product

Resources

About